HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

Latest Conference Articles

NeurologyLive® Brain Games: November 27, 2022

NeurologyLive® Brain Games: November 27, 2022

November 27th 2022, 11:00am

Disease Spotlight: Insomnia

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Future Thoughts on Improving MS Trial Design, Calculations: Carrie Hersh, DO, MSc

Future Thoughts on Improving MS Trial Design, Calculations: Carrie Hersh, DO, MSc

November 23rd 2022, 2:00pm

Cleveland Clinic

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided perspective on how the clinical community can improve trials for multiple sclerosis that help improve treatment decisions. [WATCH TIME: 4 minutes]

Expanding the Clinical Application of 2-Stage Models for Heterogenous Treatment Effects in MS: Carrie Hersh, DO, MSc

Expanding the Clinical Application of 2-Stage Models for Heterogenous Treatment Effects in MS: Carrie Hersh, DO, MSc

November 17th 2022, 2:00pm

Cleveland Clinic

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine detailed the next steps in reforming and applying new 2-stage models that improve selection for MS disease-modifying therapies. [WATCH TIME: 6 minutes]

Gantenerumab Fails to Meet End Points in Initial GRADUATE Study Data

Gantenerumab Fails to Meet End Points in Initial GRADUATE Study Data

November 14th 2022, 2:50pm

Clinical Trials on Alzheimer's Disease Conference

The GRADUATE studies, which spanned across 32 countries, showed minimal relative reduction in clinical decline for those on gantenerumab relative to placebo over a 116-week treatment cycle.

ALS Research on Genetic Testing and Counseling Provides Evidence-Based Consensus Guidelines for Clinicians

ALS Research on Genetic Testing and Counseling Provides Evidence-Based Consensus Guidelines for Clinicians

November 12th 2022, 8:00pm

Annual NEALS Meeting

Jennifer Roggenbuck, MS, LGC, an associate professor of neurology and internal medicine at The Ohio State University Wexner Medical Center, discussed her presentation on evidence-based consensus guidelines for genetic testing and counseling from the 2022 NEALS Consortium.

Ability of Nuedexta to Improve Bulbar Function in Swallowing and Speech in ALS

Ability of Nuedexta to Improve Bulbar Function in Swallowing and Speech in ALS

November 11th 2022, 10:00pm

Annual NEALS Meeting

James Wymer, MD, FAAN, discussed his presentation at the 2022 Annual NEALS meeting on improving speech and swallowing using Neudexta for patients with ALS.

Critical Takeaways, Learning Experiences From the Tofersen Trials in ALS: Timothy Miller, MD, PhD

Critical Takeaways, Learning Experiences From the Tofersen Trials in ALS: Timothy Miller, MD, PhD

November 11th 2022, 6:00pm

Annual NEALS Meeting

The codirector of the ALS Center at Washington University School of Medicine provided perspective on the lessons learned from the trials of tofersen, as it aims to become the first FDA-approved therapy specific to SOD1 ALS. [WATCH TIME: 4 minutes]

Single Dose of AstroRx Transplantation Cells Shown to be Safe for ALS

Single Dose of AstroRx Transplantation Cells Shown to be Safe for ALS

November 11th 2022, 4:00pm

Annual NEALS Meeting

A phase 1/2a clinical trial resulted in showing that a single dosing of AstroRx was safe and tolerable, at either a low or high dose, for patients with ALS.

Role of Tofersen Among Other Previously Approved ALS Therapies: Timothy Miller, MD, PhD

Role of Tofersen Among Other Previously Approved ALS Therapies: Timothy Miller, MD, PhD

November 10th 2022, 10:00pm

Annual NEALS Meeting

The codirector of the ALS Center at Washington University School of Medicine in St. Louis provided background on how tofersen would be used alongside other ALS medications if approved. [WATCH TIME: 3 minutes]

Institutional Perspectives in Neurology, Chaired by Robert T. Naismith, MD

Institutional Perspectives in Neurology, Chaired by Robert T. Naismith, MD

November 10th 2022, 5:00am

Institutional Perspectives in Neurology: Multiple Sclerosis

Chaired by Robert T. Naismith, MD, of Washington University in St. Louis, the presentations also feature Salim Chahin, MD, MSCE; Anne H. Cross, MD; Gregory F. Wu, MD, PhD; and Matthew R. Brier, MD, PhD. [WATCH TIME: 1 hour, 55 minutes]